Plerixafor (Mozobil).
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001596:Benzylamines; D003131:Combined Modality Therapy; D000080027:Cyclams; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor